<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Yueguo</style></author><author><style face="normal" font="default" size="100%">Zhang, Ning</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Association between HER-2 Over-Expression and Prognosis in Human Osteosarcoma: a Meta-Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">367-372</style></pages><doi><style  face="normal" font="default" size="100%">10.1007/s11805-008-0367-x</style></doi><volume><style face="normal" font="default" size="100%">5</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">OBJECTIVE Various studies examining the relationship between HER-2 over-expression and the response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results. The purpose of the current study was to evaluate the relation of HER-2 status with the response to chemotherapy and clinical outcome in osteosarcoma.METHODS We conducted a meta-analysis of 6 studies that evaluated the correlation between HER-2 status and histologic response to chemotherapy and 2-year survival. Data were synthesized in summary receiver operating characteristic curves and with summary likelihood ratios (LRs) and relative risk.RESULTS The quantitative synthesis showed that HER-2 status is not a prognostic factor for the response to chemotherapy. The positive LR was 1.27 (95% confidence interval, 0.91~1.77), and the negative LR was 0.68 (95% confidence interval, 0.38~1.22). There was no significant between-study heterogeneity. HER2-positive status tended to be associated with a worse 2-year survival, but the overall results were not formally statistically significant.CONCLUSION HER-2 status is not associated with the histologic response to chemotherapy in patients with osteosarcoma, whereas HER-2 positive patients may be associated with decreased survival.</style></abstract></record></records></xml>